11 Oct 2016 |
Cabozantinib superior to sunitinib in phase II study of metastatic RCC |
Genitourinary cancers -
Anticancer agents & Biologic therapy |
11 Oct 2016 |
Selumetinib plus docetaxel fails to show significant benefits over docetaxel alone in KRAS-mutant NSCLC |
Lung and other thoracic tumours |
11 Oct 2016 |
Custirsen: Disappointment so far despite a strong biological rationale |
Genitourinary cancers -
Anticancer agents & Biologic therapy |
11 Oct 2016 |
Immune checkpoint inhibitors for urothelial cancer: New hope with new options |
Genitourinary cancers -
Anticancer agents & Biologic therapy |
11 Oct 2016 |
ESMO and ASCO working together to take better care of our patients |
|
11 Oct 2016 |
ESMO 2016: Daily Reporter Editorial Team highlights |
|
11 Oct 2016 |
Advancing the treatment of sarcoma |
Sarcomas -
Anticancer agents & Biologic therapy |
10 Oct 2016 |
ESMO 2016: Metformin Significantly Lowers the Risk of Cancer Progression in Patients with Diabetes and Advanced pNETs |
Endocrine and neuroendocrine tumours -
Anticancer agents & Biologic therapy |
10 Oct 2016 |
ESMO 2016: The NETwork! Translational Programme Facilitates Genomic Analysis of Neuroendocrine Tumours |
Translational research -
Endocrine and neuroendocrine tumours |
10 Oct 2016 |
ESMO 2016: Clinical Benefit Demonstrated with Everolimus and Pasireotide LAR Alone or in Combination in the First Randomised, Prospective Study Entirely Dedicated to Advanced Lung and Thymic Carcinoids |
Endocrine and neuroendocrine tumours -
Anticancer agents & Biologic therapy |
10 Oct 2016 |
Controversy of the Day Biosimilars and bioequivalents: A wise choice in a demanding treatment landscape? |
Anticancer agents & Biologic therapy |
10 Oct 2016 |
Precision medicine: Evolving trial design for targeted treatment |
Personalised medicine |
10 Oct 2016 |
Female oncologists: Still paying the price for being a woman |
|
10 Oct 2016 |
First-line immunotherapy for advanced NSCLC: A chink in nivolumab’s armour? Greater patient selection needed! |
Lung and other thoracic tumours |
10 Oct 2016 |
ESMO 2016: Meta-Analysis Confirms Superiority of Concomitant Over Induction Chemotherapy in Non-Metastatic HNSCC |
Head and neck cancers |